Company intelligence / Profile preview
RS Oncology
Cambridge, Massachusetts, United Statesrsoncology.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
RSO-021, the company's lead compound, has completed Phase 1 clinical trials and is currently in Phase 2 of the MITOPE study. Results from the Phase 1 trial were presented at ASCO 2024. The drug targets PRX3, a key defense against oxidative stress in cancer cells.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesSynthetic peptides
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on RS Oncology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RS Oncology.